Siemens Energy Q3 Profit Beats Forecast as AI-Driven Power Demand Fuels Growth 
Qantas Shares Climb as Long-Haul Pilot Deal Eases Strike Concerns 
AMP Shares Surge 13% After Strong Profit and A$150 Million Buyback 
Western Digital Q4 Earnings Beat Estimates as FY2027 Outlook Tops Expectations 
Nintendo Shares Jump as Switch 2 Sales Boost Earnings 
Airbnb Stock Jumps After Q2 Earnings Beat, Strong 2026 Outlook 
Meta AI Model Exploits Security Flaw During Cybersecurity Test, Raising AI Safety Concerns 
Daimler Truck Q2 Profit Falls 18%, 2026 Outlook Raised 
Samsung, SK Hynix Test AMEC Chipmaking Tools for China Backup Plan 
Jetstar to Charge for Overhead Cabin Bags From February 
Moderna Wins FDA Approval for mFLUSIVA mRNA Flu Vaccine for Adults 50+ 
Cloudflare Stock Jumps 15% as Earnings Beat Estimates, 2026 Outlook Raised 
SanDisk Q4 Earnings Beat Estimates as Q1 Revenue Outlook Meets Expectations 
DoorDash Q2 Revenue Jumps 36% as Orders and DashPass Growth Drive Results 
Novo Nordisk Raises 2025 Outlook Despite Wegovy Pill Miss and CagriSema Setback 
Alibaba Plans Revenue-Sharing Model for Qwen3.8-Max AI Commercial Users 
Sinopec Boosts Russian ESPO Oil Purchases as Middle East Supply Tightens 
NEW YORK, March 13, 2018 -- In a release issued under the same headline earlier today by Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT) please note that the conference date should be March 20, not March 19 as previously stated. The corrected release follows.
Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced management will be participating in the following investor conference:
- Oppenheimer 28th Annual Healthcare Conference on March 20, 2018 at 10:20 a.m. Eastern Time
Webcast information for this event will be available on the Investors page of Intercept's website at http://ir.interceptpharma.com. Archived webcasts will be available on Intercept's website for approximately two weeks.
About Intercept
Intercept is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, including primary biliary cholangitis (PBC), nonalcoholic steatohepatitis (NASH), primary sclerosing cholangitis (PSC) and biliary atresia. Founded in 2002 in New York, Intercept now has operations in the United States, Europe and Canada.
CONTACT: For more information about
Intercept Pharmaceuticals, please contact:
Intercept Pharmaceuticals:
Mark Vignola
+1-646-747-1000
[email protected]
Media inquiries: [email protected]
Investor inquiries: [email protected]
